Back to Search
Start Over
Melanocyte-specific CD49a + CD8 + T cells in vitiligo lesion potentiate to maintain activity during systemic steroid therapy.
- Source :
-
The Journal of dermatology [J Dermatol] 2023 May; Vol. 50 (5), pp. 710-714. Date of Electronic Publication: 2022 Dec 14. - Publication Year :
- 2023
-
Abstract
- Vitiligo is a common depigmenting skin disease that is often difficult to treat. Even if repigmentation is achieved by treatment, recurrence in the same lesion is often found within a year after stopping treatment. As a background of these issues, a subset of CD8 <superscript>+</superscript> T cells that recognize melanocyte-specific antigens or CD49a <superscript>+</superscript> tissue-resident memory T cells that reside in the vitiligo lesion are thought to be involved. We investigated the MHC class I-restricted tyrosinase pentamer-positive CD8 <superscript>+</superscript> skin T cells in a progressive generalized vitiligo patient with HLA-A*02:01 who showed resistance to intravenous methylprednisolone pulse therapy. We found that HLA-A*02:01-restricted tyrosinase pentamer-positive CD8 <superscript>+</superscript> T cells remained in the lesions after the treatment and expressed IFN-γ and granzyme B. Interestingly, the expression of these cytokines in the pentamer-negative CD8 <superscript>+</superscript> T cells was decreased after intravenous methylprednisolone pulse therapy. These findings suggest that, in vitiligo patients, melanocyte-specific CD49a <superscript>+</superscript> CD8 <superscript>+</superscript> T cells are in a potent activation state that is uncontrolled despite systemic immunosuppressive treatment, which may contribute to treatment resistance and local recurrence.<br /> (© 2022 Japanese Dermatological Association.)
Details
- Language :
- English
- ISSN :
- 1346-8138
- Volume :
- 50
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- The Journal of dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 36514908
- Full Text :
- https://doi.org/10.1111/1346-8138.16680